Improving lung cancer screening: An equitable strategy through a tobacco treatment clinic.

Health equity Lung cancer screening Tobacco

Journal

Preventive medicine reports
ISSN: 2211-3355
Titre abrégé: Prev Med Rep
Pays: United States
ID NLM: 101643766

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 12 04 2021
revised: 06 09 2021
accepted: 12 09 2021
entrez: 3 1 2022
pubmed: 4 1 2022
medline: 4 1 2022
Statut: epublish

Résumé

Annual screening with low dose chest tomography has been adopted for those at high risk to aid in the early detection of lung cancer. In addition to screening, it is recommended that such persons receive evidence-based smoking-cessation. However, both lung cancer screening and evidence-based smoking-cessation strategies are underutilized in the US. We review the impact of a dedicated Tobacco Treatment Clinic (TTC), delivering evidence-based smoking cessation strategies, on lung cancer screening enrollment. Patients of the TTC, aged 50 years or older, having a minimum 20-pack-year smoking history were included. All patients had records reviewed to see if they had received lung cancer screening; if their lung cancer screening was achieved through the TTC, this was documented as "initial screening" versus "continued screening or surveillance". Sociodemographic variables were collected as well. As for results, between January 2019 to February 2020, 92 patients enrolled in the TTC and fulfilled criteria for lung cancer screening. The mean age was 65.7 ± 8.3 years old, with 58 (63.0%) of the patients being female. Seventy-five (81.5%) patients were African American. Of the 92, 68 (73.9%) patients had lung cancer screening, with 51 patients receiving their first lung cancer screening scan through the TTC. In conclusion, through enrollment in a dedicated TTC, a significant proportion of patients were able to access lung cancer screening for the first time. Further, many of these patients were of minority status. Having a dedicated TTC may improve current health equity gaps in lung cancer screenings in certain US populations.

Identifiants

pubmed: 34976626
doi: 10.1016/j.pmedr.2021.101558
pii: S2211-3355(21)00248-5
pmc: PMC8683889
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101558

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Transl Lung Cancer Res. 2019 May;8(Suppl 1):S88-S94
pubmed: 31211109
CA Cancer J Clin. 2018 Jul;68(4):297-316
pubmed: 29846940
Thorac Surg Clin. 2015 May;25(2):199-203
pubmed: 25901563
Am J Prev Med. 2019 Jan;56(1):66-73
pubmed: 30467092
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
Oncol Nurs Forum. 2014 May;41(3):E203-10
pubmed: 24769603
Ann Am Thorac Soc. 2021 Feb;18(2):187-190
pubmed: 33052710
Am J Public Health. 2011 Apr;101(4):699-706
pubmed: 21330593
J Natl Med Assoc. 2018 Oct;110(5):424-427
pubmed: 30129479
J Cancer Educ. 2020 Aug;35(4):678-681
pubmed: 30852789
Health Educ Behav. 2013 Jun;40(3):266-73
pubmed: 22984217
Prev Med Rep. 2018 Feb 03;10:49-54
pubmed: 29552458
JAMA Oncol. 2019 Sep 1;5(9):1318-1324
pubmed: 31246249
CA Cancer J Clin. 2013 Mar-Apr;63(2):107-17
pubmed: 23315954
Am J Respir Crit Care Med. 2020 Jul 15;202(2):e5-e31
pubmed: 32663106
J Thorac Oncol. 2021 Jan;16(1):37-53
pubmed: 33188913
Ann Intern Med. 2014 Mar 4;160(5):330-8
pubmed: 24378917
Am J Public Health. 2017 Aug;107(8):1248-1250
pubmed: 28700293
Clin Lung Cancer. 2020 May;21(3):e206-e211
pubmed: 32001154
N Engl J Med. 2018 Jun 28;378(26):2456-2458
pubmed: 29949490
Radiology. 2019 Feb;290(2):278-287
pubmed: 30620258
JAMA Oncol. 2017 Sep 1;3(9):1278-1281
pubmed: 28152136
Ann Intern Med. 2018 Feb 6;168(3):229-232
pubmed: 29297008
Cancer. 2020 Oct 1;126(19):4269
pubmed: 33372689
Am J Public Health. 2007 Aug;97(8):1503-9
pubmed: 17600268
BMC Cancer. 2020 Jun 16;20(1):561
pubmed: 32546140
J Natl Compr Canc Netw. 2018 Apr;16(4):412-441
pubmed: 29632061

Auteurs

Panagis Galiatsatos (P)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
The Johns Hopkins Tobacco Treatment Clinic, Johns Hopkins Bayview Medical Center, Baltimore, MD, United States.
Office of Diversity, Inclusion, and Health Equity, Johns Hopkins Medicine, Baltimore, MD, United States.
Sidney Kimmel Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine.

Raiza Schreiber (R)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Kamala Green (K)

Baltimore City Health Department, Baltimore City, MD, United States.

Rohan Shah (R)

The Ohio State University College of Medicine, Columbus, OH, United States.

Hans Lee (H)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

David Feller-Kopman (D)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Lonny Yarmus (L)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Jeffrey Thiboutot (J)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Cheng Ting Lin (CT)

Department of Radiology, Johns Hopkins Medicine, Baltimore, MD, United States.

Norma Kanarek (N)

Sidney Kimmel Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine.
Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

Classifications MeSH